Common Stock and Stockholders' Equity (Deficit) - Additional Information (Details)
|
|
|
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
|
|
|
Apr. 15, 2019
shares
|
Apr. 14, 2019
shares
|
Apr. 11, 2019
purchase_period
shares
|
Mar. 31, 2019
shares
|
Apr. 30, 2019
USD ($)
equity_incentive_plan
$ / shares
shares
|
Apr. 30, 2018
USD ($)
$ / shares
shares
|
Jan. 31, 2019
USD ($)
shares
|
Jun. 30, 2018
$ / shares
shares
|
Jan. 31, 2018
shares
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
| Number of shares issued (in shares) |
|
|
|
|
0
|
|
|
|
|
| Number of shares outstanding (in shares) |
|
|
|
|
0
|
36,000,534
|
41,273,345
|
|
36,000,534
|
| Number of equity incentive plans | equity_incentive_plan |
|
|
|
|
2
|
|
|
|
|
| Number of shares authorized for grant (in shares) |
|
|
|
|
12,431,920
|
|
23,929,932
|
|
|
| Options granted (in shares) |
|
|
|
3,041,000
|
3,682,821
|
|
|
|
|
| Number of shares available for grant (in shares) |
|
|
|
|
12,431,920
|
|
2,221,216
|
|
|
| Weighted average grant date fair value of stock options (in dollars per share) | $ / shares |
|
|
|
|
$ 10.58
|
$ 3.63
|
|
|
|
| Aggregate intrinsic value of stock options exercised | $ |
|
|
|
|
$ 19,900,000
|
$ 2,800,000
|
|
|
|
| Stock-based compensation expense | $ |
|
|
|
|
4,812,000
|
$ 3,157,000
|
|
|
|
| Unrecognized compensation cost related to unvested stock options | $ |
|
|
|
|
$ 64,200,000
|
|
$ 30,600,000
|
|
|
| Unrecognized compensation cost related to unvested stock options, period for recognition |
|
|
|
|
3 years 8 months 12 days
|
|
2 years 8 months 12 days
|
|
|
| Common stock |
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
| Number of shares as a result of conversion (in shares) |
|
41,273,345
|
|
|
41,273,345
|
|
|
|
|
| Conversion ratio |
|
1
|
|
|
|
|
|
|
|
| Number of shares called by warrant |
|
|
|
|
|
|
|
648,092
|
|
| Exercise price (in dollars per share) | $ / shares |
|
|
|
|
|
|
|
$ 0.01
|
|
| Exercise of common stock warrants (in shares) |
647,822
|
|
|
|
737,807
|
|
|
|
|
| Stock options |
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
| Expiration period |
|
|
|
|
10 years
|
|
|
|
|
| Vesting period |
|
|
|
|
4 years
|
|
|
|
|
| ESPP |
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
| Number of shares authorized for grant (in shares) |
|
|
1,850,000
|
|
|
|
|
|
|
| Offering period |
|
|
24 months
|
|
|
|
|
|
|
| Number of purchase periods within each offering period | purchase_period |
|
|
4
|
|
|
|
|
|
|
| Purchase period |
|
|
6 months
|
|
|
|
|
|
|
| Purchase price as a percentage of fair market value of stock on the offering date or the purchase date |
|
|
85.00%
|
|
|
|
|
|
|
| Stock-based compensation expense | $ |
|
|
|
|
$ 400,000
|
|
|
|
|
| Amount withheld on behalf of employees for future purchase | $ |
|
|
|
|
$ 0
|
|
|
|
|
| Shares purchased (in shares) |
|
|
|
|
0
|
|
|
|
|
| 50% vest over four years from grant date | Stock options |
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
| Vesting period |
|
|
|
4 years
|
|
|
|
|
|
| Vesting percentage |
|
|
|
50.00%
|
|
|
|
|
|
| 50% vest over five years from grant date | Stock options |
|
|
|
|
|
|
|
|
|
| Subsidiary, Sale of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
| Vesting period |
|
|
|
5 years
|
|
|
|
|
|
| Vesting percentage |
|
|
|
50.00%
|
|
|
|
|
|